<DOC>
	<DOCNO>NCT00001436</DOCNO>
	<brief_summary>The suppression IGF-I growth hormone may significantly alter pathobiology osteosarcoma . SMS 201-955 pa LAR long act analog Somatostatin inhibit pituitary release growth hormone , reduce level circulate IGF-I . Additional data tamoxifen usage also demonstrate reduction circulate IGF-I level . The degree suppression IGF-I growth hormone determine two dose level SMS 291-955 pa LAR . Tamoxifen add two cohort determine additive effect tamoxifen SMS 201-955 pa LAR lead additional reduction circulate IGF-I growth hormone level . Arginine-stimulated GH test ass level growth hormone blood administer pre-treatment evaluation three time , one time week 2 , 8 , 16 , 28 , 40 , 52 , one month post last dose SMS 201-955 pa LAR . The four cohort study receive 60 90 mg SMS 201-955 pa LAR injectable every four week 52 week . Two cohort receive 10 mg Tamoxifen daily basis .</brief_summary>
	<brief_title>A Phase I Study OncoLAR速 ( Registered Trademark ) ( NSC 685403 ) With/Without Tamoxifen Patients With Osteosarcoma</brief_title>
	<detailed_description>Osteosarcoma common primary bone malignancy childhood adolescence . Its peak age onset suggest possible contribution pathogenesis tumor endogenous hormonal milieu , accompanies adolescent growth spurt . In support , recent vitro vivo laboratory investigator suggest Insulin-like growth factor I ( IGF I ) may play important role pathobiology osteosarcoma . Somatostatin ( longer-acting analogue ) directly inhibit pituitary release growth hormone , thereby indirectly reduce level circulate IGF I . Other data also demonstrate anti-estrogen , tamoxifen , significantly reduce circulate IGF I level . We propose administer long act somatostatin analog , OncoLAR速 ( Registered Trademark ) , alone combination tamoxifen patient osteosarcoma . The degree suppression circulate IGF I growth hormone level determine two dose level OncoLAR速 ( Registered Trademark ) alone combination tamoxifen determine whether addition tamoxifen OncoLAR速 ( Registered Trademark ) lead significant additional reduction circulate IGF I growth hormone level .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Must diagnose osteosarcoma age 25 year . Patient must biopsy proven osteosarcoma either : ) active tumor available standard therapy option ; b ) metastatic osteosarcoma diagnosis , complete therapy evidence active disease ; , c ) statuspost surgery recurrent osteosarcoma , either local metastatic recurrence , free disease CT scan . Measurable disease require . Patients serum creatinine &amp; lte ; 2.0 mg/dL creatinine clearance &amp; gte ; 40 ml/min per 1.73m ( 2 ) ( serum creatinine &amp; gte ; 2.0 mg/dL ) . Patients normal thyroid function . Patients total bilirubin , SGOT SGPT &lt; twice upper limit normal . Patients normal direct bilirubin total direct bilirubin abnormal . Patients bone marrow criterion : ANC &gt; 1500/mm ( 3 ) platelet count &gt; 100,000/mm ( 3 ) . Patients without history insulindependent diabetes mellitus current insulin requirement . Fasting morning blood glucose &lt; 150 mg/dL . Patients ECOG performance status 0 , 1 2 life expectancy least 8 week . Patients chemotherapy radiation therapy within past 2 week recover acute side effect prior antineoplastic therapy . Patients document negative HIV serology within past 6 month . Postmenarcheal patient must document negative urine serum pregnancy test ( BHCG ) ; indicate , patient must willing take oral contraceptive appropriate contraceptive avoid pregnancy period treatment . Patient , parent guardian must give informed consent . No pregnant lactate woman . No woman childbearing potential unable unwilling use appropriate contraceptive period treatment . No patient uncorrected hypothyroidism . No patient insulindependent diabetes mellitus fast blood glucose &amp; gte ; 150 mg/dL . No patient HIV infection . No patient history thromboembolic event require prophylaxis thromboembolic event anticoagulant entry Cohort III begin . Patients history symptomatic gallbladder disease must cholecystectomy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Hormone Interactions</keyword>
	<keyword>IGF-I</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Recurrent</keyword>
</DOC>